The role of Human xanthine oxidoreductase (HXOR)and anti ...



The role of Human xanthine oxidoreductase (HXOR), anti-HXOR antibodies and microorganisms in synovial fluid of patients with joint inflammation

Najah Al- Muhtaseb 1* [pic], Elham Al-Kaissi 2*, Abdul Jalil Thawaini 3, Zuhair Muhi eldeen 1 , Sabah Al- Muhtaseb 4, Badiee Al-Saleh5

1Department of Medicinal chemistry and Pharmacognosy, Faculty of Pharmacy, Petra University, Amman, Jordan

2Department of Pharmaceutics and biotechnology, Faculty of Pharmacy, Petra University, Amman, Jordan

3Department of Basic sciences, Faculty of Pharmacy, Philadelphia University, Amman, Jordan

4Department of Allied Medical Sciences, Faculty of Al-Balqa , University of Zarqa, Zarqa, Jordan

5Outpatient Clinic, Rheumatologist, Amman, Jordan

• P.O. Box 961343 Amman, Jordan, Fax 00962-6-5715551, Tel. 00962-6-05715546

E mails:

1naj_nim@

2 Kaielham@

3 ajthaini@

1b Eldeenz@

4sabahesa@

5 badie_saleh@

* Contributed equally

Abstract

Objectives: This work is to investigate the levels of human xanthine oxidoreductase (HXOR), its antibodies and microorganisms in synovial fluid of patients with untreated rheumatoid joint diseases and to assess a possible relationship between severity of the inflammatory condition and the level of anti-XOR titers.

Methods: Synovial fluids were collected from sixty four patients with rheumatoid joint diseases who had not been treated with corticosteroid or disease modifying antirheumatic drugs prior to study. Sixty four age matched individuals were included as control. XOR proteins level and anti XOR antibodies were determined in the blood and synovial fluid, using human XOR as antigen, by enzyme linked immunosorbent assay (ELISA technique). C-reactive protein, ESR and rheumatoid factors were measured in patient's blood, and were culture for bacteria and fungi.

Results: The titers of XOR protein in the synovial fluid of patients with rheumatoid arthritis were 90.43 ± 23.37 µg/ml (mean ± SD, n=29) and up to 62.42 ± 8.74 µg/ml (mean ± SD, n=35) in other joint inflammation. Anti-HXOR antibodies titers in patients were (167.72 ± 23.64 µg/ ml, n= 64) which was significantly higher in rheumatoid arthritis patients compared to patients with other joint inflammations. No microorganisms were detected.

Conclusions: A good correlation was found between the severity of the disease and the levels of HXOR protein. In contrast, it seems that anti-HXOR antibodies in synovial fluids have a protective role as high concentrations against XOR were detected in inflammatory arthritis. These antibodies play role in eliminating XOR from synovial fluids (positive role). However, immune complex formation could activate complement and participate in propagating the inflammatory cycle. Synovial aspirate Ordinary microbial cultures were negative for any bacteria or fungi but that does not exclude organisms of special culture requirements.

Keywords: synovial fluid, human xanthine oxidoreductase (HOXR), ELISA, rheumatoid joint diseases. free radical. .

Introduction

In recent years, free radicals reactions and other reactive intermediates produced in normal metabolic processes have been implicated in the pathogenic mechanism of a wide range of diseases, including inflammatory diseases [1] as acute coronary syndrome [2] and others cardiovascular diseases [3]. Similarly pathogenic organisms such as parvovirus B19, rubella, hepatitis B and C, herpes [4-10], Epstein-Barr virus [11] and retroviruses could also serve as infectious causes of Rheumatoid arthritis like disease. Synovial human T lymphotropic virus type 1 (HTLV-1) infection is associated with chronic arthritis [4].

Rheumatic joint disease is a chronic syndrome of ambiguous aetiology and is characterized by non- specific inflammation of the peripheral joints with joint swelling, morning stiffness, destruction of articular tissues and joint deformities. One particular type of tissue injury from free radicals is reoxygenation injury following reperfusion of ischemic tissue [12-17]. Rheumatoid synovitis is usually accompanied by increased synovial effusions. Damage to bone and cartilage of synovial tissue is mediated by metabolic free radical sources such as xanthine oxidoreductase (XOR) and others. Xanthine oxidoreductase (XOR) is a complex metalloflavoprotein which plays a key role in catalysing the oxidation of a wide range of substrates (purine, pterins, dinucleotides, and aldehydes) [18]. The enzyme is a homodimer of approximately 300KDa [19]. XOR exists into 2 different but interconvertible forms; xanthine dehydrogenase (XDH, EC 1.1.1.204) and xanthine oxidase (XO, EC 1.1.3.22) [19-20]; the former is the dominant form. XOR produces reactive oxygen species (ROS), superoxide (O -2) or hydrogen peroxide (H2O2) respectively [21]. The capacity to generate such ROS has led to a great deal of interest in XOR as a pathogenic factor in many instances of ischaemia – reperfusion injury in various organs [19, 22-25] including inflammatory joint and rheumatic diseases[15-17]. Xanthine oxidase is the first registered biological source of oxygen free radicals and plays the leading role in the pathogenesis of tissue damage by production of superoxide anion, hydrogen peroxide, and hydroxyl radical [26]. There is substantial evidence that XOR participates in the pathophysiology of many diseases [27].

Rheumatoid arthritis (RA) is the most common chronic inflammatory arthritis that affects about 1% of adults [28]. There are no specific laboratory tests specific for RA; diagnosis depends on a constellation of signs and symptoms that can be supported by serology and radiographs [29-31]. Some RA patients show evidence of autoimmunity long before the appearance of clinical arthritis [32]. .

The presence of human anti XOR antibodies was initially reported by Oster et al [33]. Bruder et al [34] confirmed the existence of such antibodies, and showed them to be IgG. The amount of anti-XOR antibody in normal healthy humans represents 1-8% of total IgG. Levels of these antibodies were shown to be elevated in patients suffering from myocardial infarction [35]. Ng et al [36] found by ELISA technique that the IgM anti-XOR antibodies in healthy humans varied from 0.32-1.8% of total IgM, whereas IgG anti-XOR level represented only 0.02-0.4% of total IgG. Ng and Lewis [37] reported the presence of circulating XOR-anti-XOR immune complexes (XORICs) in healthy humans. The complex containing antibodies of IgG and IgM classes, representing < 20% of total anti-XOR antibodies. The levels of these complexes correlate with the anti-XOR antibody titers [38]. Rheumatoid arthritis (RA) is characterized by the appearance of auto-antibodies of types IgM, IgG and IgA known as rheumatoid factors (RF) that react essentially against autologous IgG [39]. Immune complexes activate complement. Complement activation induces inflammatory reaction [40], which contributes to the constitution of a vascular formation leading to cartilage destruction and bone erosion [41-43]. XOR present in the synovium could be liberated by synovium destruction and could play a role in post- ischemic reperfusion of rheumaroid synovium [17] contributing to the characteristics signs and symptoms of radical attack present in synovial fluid. XOR concentration is significantly raised in patients suffering from RA, up to 60 times in synovium [16] compared to healthy humans or patients with other non- rheumatic diseases.

The detection of xanthine oxidoreductase in human synovium is therefore of importance as a first step in the investigation of possible mechanisms of radical generation peculiar to a reperfusion phase of synovial injury. The aim of this work is to investigate the presence of human xanthine oxidoreductase, its antibodies in synovial fluid and the possible microbial aetiology of the inflammation in untreated patients suffering from rheumatoid arthritis (rheumatoid factor + ve) and other joint inflammatory diseases (rheumatoid factor – ve). .

Materials and methods

Subjects

Sixty four patient with rheumatoid joint disease and 64 age and sex matched controls were included in the study. All patients fulfilled the revised American College of Rheumatology (ACR) criteria for rheumatoid arthritis [23]. Consent for all procedures was obtained from each individual. The study was approved by the hospital ethics committee. Preliminary evaluation consisting of a brief medical history, smoking, alcohol habits and physical examinations was performed. Patients with any history of liver diseases, diabetes mellitus, respiratory disorders and cardiovascular diseases were excluded. None had been treated with corticosteroids or disease modifying anti-rheumatic drugs prior the study.

A pooled high titer anti-XOR and immune complexes (XORIC) human sera from volunteer donors were served to build standard curves.

Rheumatoid factor detection

Rheumatoid factor is detected by latex agglutination test using appropriate plates from Behring (Germany) according to the manufacturer recommendations. Fifty µL of latex coated with human IgG was added to different dilutions from each serum sample. Negative and positive sera were used as controls. After two minutes a clear agglutination is observed in the positive indicating the presence of RF. Sera with titer less than 20 UI/ml were considered negative according to the manufacturer recommendation.

Milk and reagents:

Human breast milk was kindly donated by mothers who had that in excess at the special care unit of the maternity hospitals; human milk was freshly collected and stored at -20oC until use.

Unless otherwise stated, all other reagents were purchased from sigma (Poole, UK).

CRP latex agglutination was purchased from Genzyme diagnostics (Kent, UK).

Purification of human xanthine oxidoreductase (XOR)

Purification of human XOR was carried out according to the previously described protocol for human milk [22]. The purified enzyme was dialysed overnight against 3 L of 50 mM sodium / Bicine buffer pH8.3 and processed as reported by Bejamin et al [44]. Enzyme activity tests were then carried out. Purified XOR enzyme was found to have more than 75% in the oxidase form.

Total protein estimation

Protein estimation for XOR enzyme was carried out according to the method of Bradford [45]. The enzyme purity was assessed on protein / flavin ratio (PFR=A 280nm / A450nm). An enzyme sample with a PFR value 5-5.2 is widely accepted to be pure.

Xanthine oxidase activity assay

Total xanthine oxidase activity of the synovial fluid was determined by measuring the rate of oxidation of xanthine to uric acid spectrophotometrically at 295 nm in a Cary 100 spectrophotometer, using a molar absorption coefficient (ε ) of 9.6 mM-1 [46]. Assays were performed at 25.0 ± 0.2oC in air-saturated 50 mM Na / Bicine buffer, pH 8.3, containing 100µM xanthine. Total (oxidase plus dehydrogenase) activity was determined as above but in the in presence of 500 µm NAD+. Dehydrogenase content of an enzyme sample was determined from the ratio of oxidase and total activities.

C - reactive protein (CRP) concentration determination

CRP concentration was determined as recommended by the manufacturer. 2.4 µl of patient serum is added to 120 µl buffer solutions (pH 8.5) and mixed with 120 µl suspension of mouse anti-human CRP monoclonal antibody that is bound to latex (2mg/ml) and incubated for 5 minutes. CRP binds to the latex-bound antibody and agglutinates. The resulting agglutination was measured spectrophotometrically at 580 nm, negative and positive control samples were included. Values higher than 9.4 mg/l for females and 8.55 mg/l for males were consider as positive.

Single radial immunodiffusion assay (SRID) to determine levels of total IgG & IgM

Commercially available plates of agarose containing anti-human IgG or anti- human IgM (Behring, Germany) were used as described by Benboubetra et al [38]. Serial dilutions of purified human IgM or IgG were used to generate standard curves. Human synovial fluids or sera were dialyzed against the commercial buffer and run against anti-human IgG or anti-human IgM on the same plates as the standard curves. Plates were placed in a humidified box and stored for 48-72 hours at room temperature until the sizes of the precipitate rings were stable. Standard curve was plotted and used to determine total IgG and IgM anti- human XOR contents in synovial fluids.

Enzyme linked immunosorbent assay (ELISA)

a- For anti-HXOR antibodies

Specific human anti-XOR antibodies were determined as previously described by Harrison R, et al [35] and Benboubetra et al [38] with slight difference in enzyme substrate. Orthophenylene diamine(OPD) [47] was used instead of 3,3,5,5 tetramethylbenzidine (TMB). In addition to synovial fluids, each plate (Coster, Spain) included serial dilutions (200 - 6400 fold in PBS-Tween) of a standard high-titer pooled serum, in duplicate wells (100 µL / well). The absorbance was measured at 492nm, in each well using a 96 well plate reader (Diagnostics Pasteur LP200). .

b- For XOR immune complexes (XORIC) .

To determine (XORIC) polystyrene 96 well microtiter plates (Coster, Spain) were coated (100 µL / well) with diluted (1 in 40) rabbit anti-human XOR serum in sodium hydrogencarbonate (pH 9.6), then incubated overnight at 4oC and processed as described by Stevens et al [17]. XORIC concentrations were calculated from plotted standard curves of absorbance against log concentration of the standard serum for each plate, and the linear part of the curve was used to calculate the titres as a percentage of the standard. Data for ELISA was expressed as mean ± SD.

Data from patient groups were compared to each other using students t test. SigmaStat Software were used for statistical analyses, Probability values of 0.05 were considered significant

Microbiologic testing

Synovial fluids were cultured on Blood agar (BA), MacConkey's agar (MA), Chocolate Agar (CA) and Sabouraud's dextrose agar (SA) (Oxoid). BA and MA plates were incubated aerobically at 37oC, CA plates were incubated under microaerophilic condition (3% CO2), SA plates were incubated at room temperature (25o C) for 72 hours. Synovial fluids were centrifuged at 500 rpm for 5 minutes and smears from the deposit were Gram and Acid fast stained. The slides were examined by light microscopy with oil immersion lens.

Results

Latex agglutination used in determining IgM-RF factor showed that, of the 64 patients 29 were RA+ (Seropositive) and 35 were RA- (Seronegative). The Clinical and biochemical characters of the participated subjects are shown in table 1. The mean age and BMI for both rheumatoid arthritis and other joint inflammation and control subjects were comparable. ESR (after 1 hour) and CRP values were significantly elevated in patients with rheumatoid arthritis (RA+) compared with the values in patient with other joint inflammation (RA-) and to those of the control values.

The total IgG and IgM titres in the synovial fluid of patient with rheumatoid arthritis (RA+) and patients with other joint inflammation (RA-) as determined by single radial immunodiffusion assay (SRIDA) are shown in table 2.

Total IgG and IgM (mg/ml) levels were significantly higher in patient with rheumatoid arthritis in comparison to the levels in patient with other joint inflammation respectively.

Total IgG and IgM titers in blood circulation of patient with rheumatoid arthritis (RA+), other joint inflammation (RA-) and in healthy volunteers, using SRIDA are shown in table 3.

Both IgG and IgM were significantly higher in rheumatoid arthritis patients than the healthy controls. Similarly, the levels were higher in serum of patient with other joint inflammation than controls. IgG levels were more elevated in serum of patient with rheumatoid arthritis compared to other joint inflammation (P< 0.001). On the other hand total IgM was more elevated in serum of patients with other joint inflammation compared to rheumatoid arthritis.

Human XOR protein, its activity and anti-human XOR (IgG and IgM) in patient's synovial fluid were measured; the results are shown in table 4.

Human xanthine oxidase protein (HXO) concentrations were significantly elevated in patient with rheumatoid arthritis compared with the concentrations in patient with other joint inflammation (P< 0.01).

Human xanthine oxidase (HXO) activity was also significantly elevated in patient with rheumatoid arthritis (100.00 ± 47.24 nmol.min-1.mg-1) compared with the activity in patients with other joint inflammation (81.42 ± 33.22 nmol.min-1.mg-1) (P< 0.01).

Both IgG and IgM anti-HXOR levels are remarkably high, representing, in the case of anti- HXOR IgM antibodies, 6.6% of the total IgM immunoglobulin in patient with rheumatoid arthritis and 4% in patient with other joint inflammation. However anti-HXOR IgG was higher in patients with other joint inflammation compared with patients with rheumatoid arthritis.

Levels of free and immune complexes IgG and IgM anti-HXOR antibodies determined by ELISA are shown in (Table 5).

Both the free and immune complexes of anti-HXOR (IgG and IgM) were lower in patients with rheumatoid arthritis compared with the levels in patients with other joint inflammation.

Direct examination as well as aerobic and microaerophilic cultures for bacteria and fungi did not reveal the presence of microorganisms. .

Discussion

The elevated levels of ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein) reported in this study indicate the presence of inflammation in both patient groups. Patients positive for rheumatoid factor were labeled as rheumatoid arthritis (RA+) while seronegative patients were labeled as other joint inflammation (RA-).

The level of human xanthine oxidase protein and its activity is significantly high in the synovial fluid of patient with rheumatoid arthritis (90.43ug/ml, 100.00 nmol.min-1.mg-1) (Table 4) .The normal level in healthy individual as reported by others (48, 49) is 0.16-0.38 mU/g. This may be due to upregulation of the enzyme by characteristically high levels of cytokines and hypoxic nature of rheumatoid synovium. Xanthine oxidase is the first registered biological source of oxygen free radicals and plays the leading role in the pathogenesis of tissue damage by production of superoxide anion, hydrogen peroxide and hydroxyl radical. The roles of XOR in cytokine induced bone erosion promoting vasculitis have been well documented by others [15-16].

The slightly higher levels of total IgG and IgM titres in patients sera determined by SRIDA in RA+ patients compared to the levels in other joint inflammation and to the levels in the serum of control healthy are in agreement with [35, 37, 50].This is expected because of the auto-immune nature of the disease. On the other hand the results showed that synovial fluids of patients suffering from rheumatoid arthritis and other joint inflammation contained lower levels of total IgG and IgM compared to the levels of these immunoglobulines in patients serum. This disagrees with the finding of others [35, 37, 50]. This may indicate that some of those immunoglobulins were bound to the tissue or are bound in immune complexes which need to be detected by other techniques. In fact the pathology of rheumatoid arthritis is attributed to an Arthus like reaction in which immune complexes mediate the crucial role.

The high anti-HXOR titres in RA patients may be due to elevated serum and synovial fluid XOR level. In most cases, more than 50% of synovial XOR is present as oxidase form [51]. The detection of relatively high concentration of XOR enzyme in its oxidative form in rheumatoid arthritis patient synovial fluids compared to the concentration of the enzyme in other joint inflammation indicates that the enzyme XOR is liberated with lysosomal enzymes from the synovium and could be involved in cartilage destruction and bone erosion suggesting a positive correlation between the level of the enzyme and the severity of the disease.

The anti-HXOR (IgM) titres, in the synovial fluid samples, were found to be significantly higher in other joint inflammation than in RA+ patients. This finding which is also reported by others [50] could be explained by the fact that IgM- Anti XOR are more efficient in immune complex formation and consequently damage in RA+ patients due to activation of the complement system.

The levels of IgM-containing XORICs were considerably higher than those of IgG, reflecting the relative levels of the free specific antibodies. In the case of both IgM and IgG, a high proportion of specific antibodies were in the complex form (90.34, 77.06 respectively). It is worth noting that, despite the relatively high levels of circulating (complexes) XOR, corresponding enzymic activity is seldom detectable, which most probably reflects the low specific activity of the human enzyme. This was also reported by Abadeh et al [52] and Yamomoto et al [53].

Synovial aspirate were never positive for any bacteria or fungi. This was also reported by other [54].A blood culture may be more revealing if an association between RA disorder and infection with a microorganism exists. Some have reported improvement after treatment of RA patient with antibiotics [55] suggesting a microbial role. It may be useful to look for unconventional organisms such as Chlamydia and Mycoplasma as suggested by other [4, 56].

Rheumatoid arthritis may have complex pathology. In addition to the obvious effect of the rheumatoid factor, Proteus mirabilis was also incriminated. Newkirk et al [57] have found that IgM and IgA anti-Proteus mirabilis antibodies were significantly higher in patients with rheumatoid arthritis RA+ Compared with RA- arthritis, spondyloarthropathy and undifferentiated arthritis. Similarly, Tani et al [58] have found that patients with rheumatoid arthritis showed elevated levels of antibodies to Proteus mirabilis compared to ankylosing spondylitis and controls. They suggested an amino acid homology between an outer membrane haemolysin protein of Proteus mirabilis and susceptibility sequence in HLA-DR1, and DR4 subtypes. Also, Senior et. al [59] found that 33% of patients with rheumatoid arthritis had asymptomatic insignificant bacteriuria compared to 4% of age and gender matched controls. Similarly patients had significantly higher levels of IgA, IgM and IgG antibodies to Proteus mirabilis in blood and urine than controls. It is suggested that this may be the trigger for the rheumatoid arthritis condition.

Conclusions

These findings suggest that XOR may play an important role as a source of ROS in RA and in other joint inflammation which participate in self-maintenance of the diseases. Antibodies against XOR may play a major role in RA by inhibiting both xanthine and NADH oxidase activities of XOR. They may also play a key role in eliminating XOR from serum and synovial fluid. However, immune complex formation could activate the complement system and participate in self maintenance of the diseases.

Abbreviations

XOR, xanthine oxidoreductase; HXOR, human xanthine oxidoreductase; anti-XOR, antibodies (IgM or IgG) against xanthine oxidoreductase; anti-HXOR, antibodies (IgM or IgG) against human xanthine oxidoreductase; ESR, erythrocytes sedimentation rate; CRP, C- reactive protein; SD, standard deviation; ELISA, enzyme linked immunosorbent assay; HTLV-1, human T lymphotropic virus type 1; ROS, reactive oxygen species; H2O2, hydrogen peroxide; O-2, superoxide; XDH, xanthine dehydrogenase; RA, rheumatoid arthritis; XORICs, xanthine oxidoreductase -anti- xanthine oxidoreductase immune complexes; HXORICs, human xanthine oxidoreductase -anti- xanthine oxidoreductase immune complexes; RF, rheumatoid factors; ACR, american college of rheumatology; PFR, protein / flavin ratio; NAD+, nicotinamide adenine dinucleotide; NADH, nicotinamide adenine dinucleotide hydrogen; SRID, single radial innunodiffusion; OPD, orthophenylene diamine; TMB, tetramethyl benzidine; BA, blood agar; SA, sabouraud's dextrose agar; BA, blood agar; CA, chocolate; IgM-RF, IgM –rheumatoid factor; RA+, positive rheumatoid factor;RA-, negative rheumatoid factor; BMI, body mass index; HLA-DR1, human leukocyte antigen subtypeDr1; DR4, human leukocyte antigen subtype DR4; PBS, phosphate buffer solution.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

None

Acknowledgements

None

References

1. Chung HY, Baek BS, Song SH, Kim MS, Huh JI, Shim KH, Kim KW, and Lee KH:

Xanthine dehydrogenase / Xanthine oxidase and oxidative stress. Age 1997, 20: 127- 140.

2. Cheng-xing S, Hao-zhu C, and Jun-bo G: The role of inflammatory stress in acute

coronary syndrome. Chinese medical J 2004, 117: 133-139.

3. Dawson J, and Walters M: Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease Br J Clin Pharmacol.2006 ,62: 633-644.

4. Carty SM, Snowden N, Silman AJ: Should infection still be considered as the most likely triggering factor for rheumatoid arthritis. Ann Rheum Dis 2004, 63: ii46-ii49

5. Griffiths DJ: Rheumatoid arthritis: a viral aetiology ?. Hosp Med. 2000, 61: 378-379.

6. Masuko-Hongo K, Kato T, Nishioka K: Virus-associated arthritis. Best Pract Res Clin Rheumatol. 2003, 17: 309-318.

7. Phillips PE: Viral arthritis. Curr Opin Rheumatol 1997, 9: 337-344.

8. Zhang L, Nikkari S, Skurnik M, Ziegler T, Luukainen R, Mottonen T, Toivanen P: Detection of herpesviruses by polymerase chain reaction in lymphocytes frm patients with rheumatoid arthritis. Arthritis Rheum.1993, 36: 1080-1086.

9. Naides SJ: Rheumatic manifestations of parvovirus B19 infection. Rheum Dis Clin North Am. 1998, 24: 375-401.

10. Katsumi E: Involvement of viral infection in rheumatoid arthritis. Pharma Med 1999, 17: 19-26.

11. Hasunuma T, Sumida T, Nishioka K: Human T cell leukemia virus type-1 and rheumatoid arthritis. Int Rev Immunol 1998, 17: 291-307.

12. Zweier JL: Measurement and characterization of post-ischemic free radical generation in isolated perfused heart. J Biol Chem 1988, 263: 1353-1357.

13. Kennedy TP, Rao NV, Hopkins C, Pennington L, Tolley E, and Hoidal JR: Role of

reactive oxygen species in reperfusion injury of the rabbit lung. J Clin Invest 1989, 83: 1326-35.

14. Sussman MS, and Bulkley GB: Oxygen-derived free radicls in reperfusion injury. Methods in Enzymology 1990, 186: 711-723.

15. Miesel R, and Zuber M: Elevated levels of xanthine oxidase in serum of patients with inflammatory and auto-immune rheumatic diseases. Inflammation 1993, 17: 551-560.

16. Blake DR, Stevens CR, Sahinoglu T, Ellis G, Gaffney K, Edmonds S, Benboubetra M, Harrison R, Jawed S, Kanczler J, Millar TM, Winyard PG, and Zhang Z: Xanthine oxidase; four roles for the enzyme in rheumatoid pathology. Biochem Soc Trans 1997, 25: 812-816.

17. Stevens CR, Benboubetra M, Harrison R, Sahinoglu T, Smith EC, and Blake DR: Localization of xanthine oxidase to synovial endothelium. Ann Rheum Dis 1991, 50: 760-762.

18. Bray RC: Molybdenum iron-sulfur flavin hydroxylases and related enzymes. In: Boyer PD, Editor. The enzymes. New York, Academic Press 1975: 299-419.

19. Harrison R: Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med 2002, 33: 774-797.

20. Martin HM, Hancock JT, Salisbury V, and Harrison R: Role of xanthine oxidoreductase as an antimicrobial agent. Infect Immun 2004, 72: 4933-4939.

21. Khan AU, Wilson T: Reactive oxygen species as cellular messengers. Chem Biol 1995, 2: 437-445.

22. Sanders SA, Eisenthal R, Harrison R: NADH oxidase activity of human xanthine oxidoreductase – generation of superoxide anion. Eur J Biochem 1997, 245:541-548.

23. Baghiani A, Harrison R, Benboubetra M: Purification and partial characterization of camel milk xanthine oxidoreductase. Arch Physiol Biochem 2003, 111: 407-414.

24. Jarasch ED Grund C, Bruder G, Heid HW, Keenan TW, Franke WW: Localization of xanthine oxidase in mammary-gland epithelium and capillary endothelium. Cell 1981, 25: 67-82.

25. Meneshian A, and Bulkley GB: The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction. Microcirculation 2002, 9: 162-175.

26. Kundalic S, Kocic G, Cosic V, Jevtovic-stoimenova t, Dordevic VB: The role of xanthine dehydrogenase L xanthine oxidase in atherogenesis in patients with hyperlipidaemia . Jugoslov Med biochem 2003, 22: 151-158

27.Berry CE and Hare JM: Xanthine oxidoreductase and cardiovascular diseases: molecular mechanisms and pathophysiology . J physiol 2004, 555: 589-606

28. Mitchell KL, Pisetsky DS: Early rheumatoid arthritis. Curr Opin Rheumatol CME 2007, 19: 278-283.

29. Machold KP, Stamm TA, Eberl GJM, Nell VKP, Dunky A, Uffmann M, et al: Very recent onset arthritis: clinical, laboratory, and radiological findings during the first year disease. J Rheumatol 2002, 29: 2278-2287.

30. Hichon CA, Peschken CA, Shaikh S, El-Gabalawy HS: Early undifferentiated arthritis. Rheum Dis Clin N Am 2005, 31: 605-626.

31. Van Aken J, Van Dongen H, Le Cessie S, Allaart CF, Breedveld FC, Huizinga TWJ, et al: Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study. Ann Rheum Dis 2006, 65: 20-25.

32. Kary S, Fritz J, Scherer HU and Burmester GR: Do we still miss the chance of effectively treating early rheumatoid arthritis? New answers from a new study. Rheumatol 2004, 43: 819-820.

33. Oster KA, Oster JB, Ross DJ: Immune response to bovine xanthine oxidzse in atherosclerotic patients. Am Lab 1975, 6: 41-47.

34. Bruder g, Jarasch ED, Heid HW: High concentration of antibodies to xanthine oxidase in human and animal sera. J Clin Invest 1984, 74: 783-794.

35. Harrison R, Benboubetra M, Bryson S, Thomas RD, Elwood PC: Antibodies to xanthine oxidase: elevated levels in patients with acute myocardial infarction. Cardioscience 1990, 1: 183-189.

36. Ng YLE, Lewis WHP, Chui SH: Enzyme linked immunosorbent assay for determination of antibodies to xanthine oxidase. Med Lab Invest 1990, 47: 30-35.

37. Ng YLE, Lewis WHP: Circulating immune complexes of xanthine oxidase in normal subjects. Br j biomed Sci 1994, 51: 124-127.

38. Benboubetra M, Gleeson A, Harris CPD, Khan J, Arrar L, Brennand D et al: Circulating anti-(xanthine oxidoreductase) antibodies in healthy human adults. Eur J clin invest 1997, 27: 611-619

39. Venn AJ, Dresser DW: Limitation of haemolytic plaque assay for IgG anti-IgG rheumatoid factor-producing cells. J Immunol Meth 1987, 102: 195-204.

40. Simon L, Claustre j, Picard JJ, Marty m, blotman F: Intra-articular osteoid osteoma of the elbow. Rheumatologie 1972, 24: 377-382.

41. Zvaifler NJ: The immunopathology of joint inflammation in rheumatoid arthritis. Adv Immunol 1973, 16: 265-336.

42. Palmer DG, Hogg N, Revell PA: Lymphocytes, polymorphonuclear leukocytes, macrophages and platelets in synovium involvef by rheumatoid arthritis. a study with monoclonal antibodies. Pathology 1986, 18: 431-437.

43. Zubler RH, Nydegger U, Perrin LH, Fehr K, McCormick J, Lambert PH, et al. Circulating and intra-articular immune complexes in patients with rheumatoid arthritis. Correlation of 125I-CIq binding activity with clinical and biological features of the disease. J Clin Invest 1976, 57: 1308-1319.

44. Godber BLJ, Schwarz G, Mendel RR, Lowe DJ, Bray RC, Eisenthal R, Harrison R: Molecular characterization of human xanthine oxidoreductase: the enzyme is grossly deficient in molybdenum and substantially deficient in iron-sulphur centres. Biochem J 2005, 388: 501-508.

45. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantitative of proteins. Anal Biochem 1976, 72: 248-254.

46. Avis PG, Bergel F, Bray RC: Cellular constituents. The chemistry of xanthine oxidase. Part III. Estimations of the cofactors and the catalytic functions of enzyme fractions of cows' milk. J Chem Soc 1956, (Perkins I): 1219-1226.

47. Rousseaux-Prevost R, De Almeida M, Arrar L, Hublau P, Rousseaux J: Antibodies to sperm basic nuclear protein detected in infertile patients by dot-immunobinding and ELISA. Am J Reproductive Immunol 1989, 20: 17-20.

48. Allen RE, Outhwaite JM, Morris CJ, and Blake DR: Xanthine oxidoreductase is present in human synovium. Annals of the Rheumatic Diseases 1987, 46: 843-845.

49. Parks DA, Granger DN: Xanthine oxidase: biochemistry distribution and physiology. Acta Physiol Scand Suppl 1986, 548: 87-99.

50. Arrar L, Hanachi N, Rouba K, Charef N, Khennouf S, Baghiani A: Anti-xanthine oxidase antibodies in sera and synovial fluid of patients with rheumatoid arthritis and other joint inflammations. Saudi Med J 2008, 29: 803-807.

51. Hanachi N, Charef N, Baghiani A, Khennouf S, Derradji Y, Boumerfeg s , et al: Comparison of xanthine oxidase levels in synovial fluid from patients with rheumatoid arthritis and other joint inflammations. Saudi Med j 2009, 30: 1422-1425.

52. Abadeh S, Killacky J, Benboubetra M, Harrison R: Purification and partial characterization of xanthine oxidase from human milk. Biochem Biophys Acta 1992. 1117: 25-32.

53. Yamomoto T, Moriwaki Y, Takahashi S et al: Determination of human plasma xanthine oxidase activity by high- performance liquid chromatography. J Chromatog B 1996, 681: 395-400

54. Hall GS, Gordon S, Schroeder S, Smith K, Anthony K, and Procop W: Case of Synovitis potenitially causedby Dolosigranulum pigrum. J Clin Microbiol 2001, 39: 1202-1203.

55. Ogrendik M: Rheumatoid arthritis is linked to oral bacteria: etiology association. Modern Rheumatollogy 2009, 19: 453-456.

56. Schaeverbeke T, Renaudin H, Clerc M, Lequen L, Vernhes JP, De Barbeyrac B, Bannwarth B, Bebear CH, and Dehais J: Systematic detection of mycoplasmas by culture and polymerase chain reaction (PCR) procedures in 209 synovial fluid samples. Br J Rheum 1997, 36: 310-314.

57. Newkirk, MM, Goldbach-Mausky, R, Senior, BW, Klippel, J, Schumucher, HR, Al-Gebalawy, HS: Elevated levels of IgM and IgA antibodies to Proteus mirabilis and IgM antibodies to E. coli are associated with early RF- Positive rheumatoid arthritis. Rheumatology 2005, 44 (11): 1433-1441.

58. Tani, Y; Tiwana, H; Hukudu,s; Nishioka,J; Fielder,M; Wilson, C; Bausal,S; Ebriager,A: Antibodies to Klebsiella, Proteus and HLA-B27 peptides in Japanese patients withAnkylosing spondylitis and rheumatoid arthritis. J. Rheumatology. 1997, 24(1): 109-114

59. Senior BW, Anderson GA, Mortey KD, and Kerv MA: Evidence the patients with rheumatoid arthritis have a symptomatic non-significant Proteus mirabilis bacteriuria more frequently than healthy controls J infect 1999, 38(2): 99-106.

Table 1: Clinical and biochemical characters of the participated subjects .

|Type of disease |No. of Subj-|Age |Height (cm) |Weight (Kg) |BMI |ESR |CRP |

| |ects |(years) | | | |(mm) | |

| | | | | | | | |

|RA - |35 |41.04± 9.1 |161.6±5.6 |69.1±6.0 |26.9±9.7 |40.3±30.4 |+ |

| | | | |

|Controls |64 |42.04± 7.7 |162.3±4.7 |

|0.97± 0.34 b |13.71 ± 4.41a |29 |RA+* |

|0.55 ± 0.20 |9.77 ± 2.71 |35 |Other joint inflammation |

* RA = Rheumatoid arthritis latex agglutination positive

** SRIDA = Single radial immunodiffusion assay

a P < 0.001 significantly higher with RA+ group

b P < 0.05 significantly higher with RA+ group

Table 3: Total IgG and IgM titres in sera of patients with rheumatoid arthritis (RA+), other joint inflammation (RA-), and healthy volunteers, using SRIDA**

|Total IgM (mg/ml) |Total IgG (mg/ml) |Number of patients |Patients |

|2.23± 1.25 a |24.52 ± 9.53a |29 |RA+* |

|3.42 ± 0.06 b |19.37 ± 5.6 b |35 |Other joint inflammation |

|1.5 ± 0.52 |13.5 ± 4.41 |60 |Pools from healthy individuals |

* RA = Rheumatoid arthritis latex agglutination positive

** SRIDA = Single radial immunodiffusion assay

a P < 0.0001 significantly differ from the control subjects

b P < 0.01 significantly differ from the other joint inflammation

Results are means ± S.D in milligrams per deciliter

Table 4: Human xanthine oxidase protein, (HXOR) activity and anti-HXOR (IgG and IgM) in patient synovial fluids

|Anti-HXOR (IgM) |Anti-HXOR (IgG) |HXOR activity |HXOR protein |No. of |Type of disease |

|μg/ml |μg/ml |nmol.min-1.mg-1 |(μg/ml) |patients | |

|131.35 ± 30.39 |36.37 ± 22.35 |100.00 ± 47.24 |90.43± |29 |RA+ |

| | | |23.37 | | |

|105.6 ± 31.36 |46.43±23.62 |81.42 ± 33.22 |62.42± |35 |Other joint inflammation |

| | | |8.74 | | |

|< 0.001 |< 0.05 |< 0.01 |< 0.01 | |P |

Table 5: IgG and IgM anti-HXOR antibodies, free (HXORAb) and immune complexes (HXORIC) determined by ELISA ( µg ml -1) in patient synovial fluid. .

|HXORIC |HXORAb | | |

|IgM |IgG |IgM |IgG | | |

|90.34± 74.96 |77.06± 38.74 |131.35 ±30.39 |36.77±22.35 |29 |RA+ |

|134.94±43.61 |86.13± 14.30 |141.09± |46.43±23.62 |35 |Others joint inflammation|

| | |31.36 | | | |

|< 0.001 |< 0.05 |< 0.01 |< 0.001 | |p |

[pic]

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download